OMNOVA Solutions Inc.

All USD millions except per-share and ratios. Source: OMNOVA FY2019 10-K Item 6 (Selected Financial Data) and MD&A, unless noted. "Derived" metrics are this analyst's calculations from reported lines. EBIT is defined as pre-tax income plus interest expense, and EBITDA as that EBIT plus depreciation & amortization. These are unadjusted GAAP-derived measures, not management's "Adjusted EBITDA."

Margins and growth (derived)

Revenue CAGR FY2015–FY2019: –3.2% (derived). FY2017–FY2019 CAGR: –3.0%.

Balance sheet

FY2016 equity is from a secondary source (Wikipedia infobox citing FY2016). Working-capital days rose from 46.8 (FY2018) to 56.8 (FY2019), mainly because of OMNOVA Portugal.

Cash flow

On buybacks: a USD 20M authorization was granted in September 2018, and no repurchases were made in Q4 FY2019 because the merger agreement prohibited them. Full-year FY2018–FY2019 repurchase amounts were not separately disclosed in retrieved text. The FY2017 financing outflow included USD 2.2M of shares withheld for employee taxes, which is not a buyback.

Ratios (derived)

The following are not computable from retrieved data and are marked not disclosed: ROIC (management tracked it but did not publish a figure in the retrieved excerpts), current ratio, debt/equity outside FY2016 (FY2016 ≈ 3.3x gross debt to equity, derived), and the cash conversion cycle (working-capital days of 46.8 and 56.8 are the nearest disclosed proxy).

Commentary on trends, inflections and drivers

1. Deliberate top-line contraction. Sales fell about USD 102M over four years. The largest single driver was Paper & Carpet, which fell from USD 166.5M in FY2017 to USD 64.1M in FY2019 (–61%) after the planned exit from commodity paper coatings and weaker commodity carpet volumes. FX was a headwind in FY2019 (–USD 11.2M) and a tailwind in FY2018 (+USD 14.7M). FY2016's –9.3% drop also reflected lower raw-material pass-through prices: COGS fell faster than sales, and gross margin peaked at 26.8%.

2. Gross margin peaked in FY2016 and eroded thereafter (26.8% → 23.9%). The cause was lost volume absorption in Performance Materials, plus raw-material lag in FY2017–18, when butadiene spiked to USD 1.42/lb in FY2017. Monomer purchases fell sharply (styrene from 129M lb to 91M lb; butadiene from 103M lb to 67M lb between FY2017 and FY2019), which shows how much commodity volume was deliberately shed.

3. Recurring "non-recurring" charges. Impairments, restructuring, FX losses and deal costs totalled USD 26.1M in FY2015, USD 17.7M in FY2016, USD 38.9M in FY2017, USD 21.1M in FY2018 and USD 41.1M in FY2019 (derived from the line items above). They effectively consumed all operating profit in three of five years. Investors therefore focused on Adjusted Segment Operating Profit. For example, the adjusted Q4 FY2019 figure was USD 7.0M versus USD 10.1M a year earlier, and adjusted diluted EPS for Q4 FY2019 was USD 0.11 versus USD 0.17.

4. FY2017 tax shock. A USD 79.9M valuation allowance on deferred tax assets (USD 75.7M in the US) plus a non-deductible USD 19.6M goodwill impairment produced the USD 87.8M net loss. This permanently impaired book equity.

5. Deleveraging stalled. Gross debt fell only from USD 366.0M to USD 332.5M between FY2016 and FY2019, despite a USD 40M Term Loan B prepayment in Q1 FY2018. That was because the Portugal acquisition and revolver usage in FY2019 offset it. Net debt was flat at about USD 275–282M.

6. FY2019 cash-flow deterioration. Operating cash flow fell from USD 56.7M to USD 24.4M, and FCF turned negative (–USD 8.7M) as earnings fell, working capital absorbed cash and capex rose to USD 33.1M. This weakened the standalone case and coincided with the board's decision to sell. At FY2019 year-end, cash of USD 50.9M was split USD 10.5M US, USD 14.2M Europe and USD 26.2M Asia.

7. Pension drag. The US defined-benefit plan was frozen (future accruals ended 1 December 2011) but underfunded. Contributions of about USD 6.3–6.5M per year were made, a further USD 6.6M was expected for FY2020, and the discount rate fell from 4.41% to 3.07%.

Guidance

There is no OMNOVA-level guidance, as the company has been a subsidiary since April 2020. The relevant guidance is Synthomer's: FY2026 EBITDA slightly ahead of the GBP 162M consensus, positive free cash flow before receivables-finance movements, and covenant leverage of 4.0–4.35x by December 2026, excluding further divestments.

Bull case (legacy OMNOVA franchises within Synthomer)

1. The specialty core proved its worth. Specialty Solutions grew from USD 441.4M to USD 513.0M (FY2017–FY2019) at about 13–15% margins. Inside a larger group with procurement scale, these chemistries (coatings resins, elastomers, oilfield polymers) are better positioned than they were standalone.

2. Portfolio surgery created value. The surfaces businesses, whose sales were roughly USD 200M (FY2019 L&F USD 153.3M plus coated fabrics USD 48.5M), were sold for USD 255M EV at about 7.7x 2021 EBITDA. That recovered close to a third of the USD 824M purchase EV and cut debt.

3. Parent inflection. H1 2026 EBITDA rose 16.4%, margins expanded 80bp to 10.1% and guidance was raised. Intumescent coatings volumes doubled, and Asian competitors' supply disruption is favouring Western producers.

Bear case

1. The deal was dilutive in hindsight. Synthomer paid EV USD 824M, about 25x FY2019 GAAP-derived EBITDA, for a business earning a GAAP-derived EBIT of USD 1M. Synthomer's subsequent covenant waivers, the GBP 150.1M FY2025 net loss and a market cap of about GBP 90M in February 2026 indicate the leverage-funded expansion of 2020–2022 (OMNOVA and the Eastman resins deal) overextended the group.

2. Parent credit fragility. Covenant leverage was 4.9x in June 2026. The April 2026 drop-down refinancing structurally subordinates the EUR 350M noteholders, and fees were paid in shares at 37.5p. Further asset sales are explicitly contemplated, so additional legacy OMNOVA lines could be sold.

3. Structural decline in Performance Materials heritage. OMNOVA's paper and carpet latex fell 61% in two years, and the performance additives trade names were impaired. Commodity latex remains exposed to raw-material shocks such as the 2026 Iran-conflict energy and monomer inflation.

Catalysts and monitorables (next 12 months)

• Confirmation of the Acrylate Monomers completion (expected end Q3 2026).

• Synthomer Q3 2026 trading update and FY2026 results (early 2027): delivery against the slightly-above-GBP-162M EBITDA guidance.

• Year-end 2026 covenant leverage against the 4.0–4.35x target.

• Any further divestments touching legacy OMNOVA chemistries, such as oil and gas or performance additives.

• Raw-material and energy price trajectory, given the Iran conflict.

• Treatment of the EUR 350M notes and future capital-structure actions.

• Continued intumescent and coatings growth (legacy Pliolite and coatings-resin relevance).

Analyst verdict

OMNOVA Solutions no longer exists as an investable security. Any user record listing it as a "public company" should be updated: it has been a wholly owned subsidiary of Synthomer plc since 1 April 2020, when Synthomer acquired it for USD 10.15 per share, an enterprise value of USD 824 million.

Judged on its record as a listed company, OMNOVA was a well-intentioned but under-capitalized transformation. Between FY2015 and FY2019, management under Anne Noonan executed a credible specialization strategy. It exited commodity paper latex, closed or converted the Akron, Calhoun and Green Bay operations, delivered ten straight quarters of specialty volume growth, and lifted Specialty Solutions to 70% of sales. That strategy could not overcome the arithmetic of a USD 330 million debt stack against GAAP-derived EBITDA of USD 32 to 65 million. Recurring impairments, a USD 79.9 million tax valuation allowance in FY2017 and raw-material lag left the company with net losses in four of five years and zero dividends since 2001. Selling to a larger strategic owner was the rational outcome, and the 79% premium to the May 2019 price rewarded shareholders.

For Synthomer, the verdict is more mixed. The acquisition delivered geographic reach and integration on schedule. The later sale of the surfaces businesses for USD 262 million in net proceeds recovered a meaningful share of the price at a respectable multiple. However, the leverage-heavy expansion of 2020–2022 contributed to the 2025–2026 balance-sheet crisis: covenant waivers, a near-50% share collapse on equity-raise fears, and a drop-down refinancing in April 2026. The H1 2026 rebound, with EBITDA up 16% and margins at 10.1%, suggests the specialty thesis that underpinned the OMNOVA deal is finally showing in the numbers.

For counterparties dealing with legacy OMNOVA brands, the key exposure is Synthomer's credit trajectory. The key watch items are whether leverage reaches 4.0–4.35x by December 2026 and whether further disposals reshape the former OMNOVA product lines.